公开(公告)号：IL249184A

公开(公告)日：2022-04-01

申请号：IL24918416

申请日：2016-11-24

Applicant: ACADEMIA SINICA

IPC: A61K39/395 ,  A61K39/00 ,  A61K45/06 ,  C07K16/24 ,  C12P21/00

Abstract: The present disclosure relates to a novel class of anti-TNFα monoclonal antibodies or antigen binding fragments comprising a homogeneous population of anti-TNFα IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-TNFα monoclonal antibodies by Fc glycoengineering. The glycoantibodies of the invention may have improved therapeutic values compared to the corresponding monoclonal antibodies that have not been glycoengineered.

公开(公告)号：ES2902032T3

公开(公告)日：2022-03-24

申请号：ES15878250

申请日：2015-07-13

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  HSU TSUI-LING ,  LOU YI-WEI ,  LIN CHIH-WEI ,  YEH SHIH-CHI ,  WU CHUNG-YI ,  WU HAN-CHUNG

IPC: C07K16/18 ,  A61P35/00 ,  C07K16/30 ,  C12P19/14

Abstract: Anticuerpo monoclonal humanizado aislado que se une específicamente a Neu5Acα2 → 3Galβ1 → 3GalNAcβ1 → 3Galα1 → 4Galβ1 → 4Glcβ1, en el que el anticuerpo comprende un VH que tiene la SEQ ID NO: 147 y un VL que tiene la SEQ ID NO: 148.

公开(公告)号：ES2901173T3

公开(公告)日：2022-03-21

申请号：ES16744256

申请日：2016-01-30

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  MA CHE ,  WU HAN-CHUNG

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/30 ,  C12P19/14

Abstract: Anticuerpo monoclonal aislado o un fragmento de unión del mismo que se une a Neu5Acα2 → 3Galβ1 → 3GalNAcβ1 → 3Galα1 → 4Galβ1 → 4Glcβ1 (hexasacárido SSEA-4), en el que el anticuerpo monoclonal aislado o el fragmento de unión del mismo es un anticuerpo desfucosilado que comprende una glicoforma de Fc unida a la región de Fc, en la que dicha glicoforma tiene la fórmula: **(Ver fórmula)** Sia2(α2-6)Gal2GlcNAc2Man3GlcNAc2 en la que el anticuerpo comprende una VH que tiene la SEQ ID NO: 147 y una VL que tiene la SEQ ID NO: 148.

公开(公告)号：IL286492D0

公开(公告)日：2021-12-01

申请号：IL28649221

申请日：2021-09-19

Applicant: ACADEMIA SINICA ,  WONG CHI HUEY ,  LO HONG JAY

Inventor： WONG CHI-HUEY ,  LO HONG-JAY

IPC: A61P35/00 ,  C07H15/18 ,  C07K16/28 ,  C07K16/32

Abstract: Disclosed are a method of preparing a saccharide that contains a 3-fluoro-sialic acid and a method of bonding it to a homogeneous antibody. Also within the scope of this invention are compounds each containing a 3-fluoro-sialic acid, monoclonal antibodies bonded to α2,6-linked 3-fluoro-sialoside terminated N-glycans, and treatment of cancer with such monoclonal antibodies.

公开(公告)号：CA3052909C

公开(公告)日：2021-10-19

申请号：CA3052909

申请日：2013-08-20

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  TSAI TSUNG-I

IPC: C12P19/18 ,  C07H15/04 ,  C12M1/40 ,  C12N9/00 ,  C12N9/10 ,  C12N9/12 ,  C12P19/00 ,  C12P19/04 ,  C12P19/30 ,  C12P19/44

Abstract: A novel UDP-Gal regeneration process and its combined use with a galactosyltransferease to add galactose to a suitable acceptor substrate. Also described herein are synthetic methods for generating Globo-series oligosaccharides in large scale, wherein the methods may involve the combination of a glycosyltransferase reaction and a nucleotide sugar regeneration process.

公开(公告)号：DK3245225T3

公开(公告)日：2021-10-18

申请号：DK15878250

申请日：2015-07-13

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  LOU YI-WEI ,  LIN CHIH-WEI ,  WU CHUNG-YI ,  WU HAN-CHUNG ,  YEH SHIH-CHI ,  HSU TSUI-LING

IPC: C07K16/18 ,  A61P35/00 ,  C07K16/30 ,  C12P19/14

公开(公告)号：AU2016249991B2

公开(公告)日：2021-03-25

申请号：AU2016249991

申请日：2016-04-12

Applicant: ACADEMIA SINICA

Inventor： WU HAN-CHUNG ,  LU RUEI-MIN ,  CHIU CHIUNG-YI ,  LIU I-JU ,  CHANG YU-LING

IPC: C07K16/28

Abstract: An isolated antibody or an antigen-binding fragment thereof having a specific binding affinity to an epitope located within the domain 1 or domain 3 of human vascular endothelial growth factor receptor 2 (VEGFR2; SEQ ID NO: 74) is disclosed. The epitope within the domain 3 of the VEGFR2 is located between amino acid residues 250 and 270 of SEQ ID NO: 74. Use of the antibody or antigen-binding fragment thereof in the manufacture of a medicament for inhibiting tumor growth, tumor angiogenesis, and/or inducing cancer cell cytotoxicity in a subject in need thereof is also disclosed. Also disclosed is a method of detecting the presence of VEGFR2 in a tumor vascular endothelial cell or a cancer cell in a biological sample.

公开(公告)号：AU2021200784A1

公开(公告)日：2021-03-04

申请号：AU2021200784

申请日：2021-02-08

Applicant: ACADEMIA SINICA

Inventor： WU CHUNG-YI ,  TSAI MING-HUNG ,  WONG CHI-HUEY

IPC: C07K16/00

Abstract: The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by FE glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased FE receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

公开(公告)号：AU2019333295A1

公开(公告)日：2021-03-04

申请号：AU2019333295

申请日：2019-08-30

Applicant: ACADEMIA SINICA ,  NATIONAL HEALTH RES INST

Inventor： SHIH CHUAN ,  CHEN CHIH-HAO ,  CHEN CHIUNG-TONG ,  WANG HWEI-JIUNG ,  HUANG KAI-FA

IPC: A61K31/4184 ,  A61P25/28 ,  C07D403/04

Abstract: Benzimidazole compounds of formula (I), shown below, are disclosed. The compounds are potent human glutaminyl cyclase inhibitors. Also disclosed is a pharmaceutical composition containing one of these compounds and a pharmaceutical acceptable carrier, as well as a method of treating Alzheimer's disease or Huntington's disease by administering to a subject in need thereof an effective amount of such a compound.

公开(公告)号：AU2015267045B2

公开(公告)日：2021-02-25

申请号：AU2015267045

申请日：2015-05-27

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI

IPC: C07K16/00

Abstract: The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.